JW Jungwo Pharmaceutical and Voronoi Collaborate on Next-Generation Anticancer Drug Development

[Asia Economy Reporter Cho Hyun-ui] JW Pharmaceutical announced on the 3rd that it has signed a joint research agreement with the bio-venture company Boronoi for the development of anticancer drugs using 'STAT3 PROTAC (Proteolysis-targeting chimera)'.

This project aims to develop innovative new drugs by applying Boronoi's protein degradation technology, 'PROTAC', to JW Pharmaceutical's small molecule anticancer drug candidate targeting 'STAT3' currently under development.

STAT3 is a protein (transcription factor) that promotes the expression of multiple genes involved in cancer cell growth, proliferation, metastasis, and drug resistance formation.

Boronoi is responsible for compound design, synthesis, and deriving clinical candidates. JW Pharmaceutical will evaluate the candidates and conduct translational clinical research to advance them to clinical stages.

JW Pharmaceutical is discovering new drug candidates that inhibit STAT3 through novel mechanisms and is currently conducting non-clinical trials and drug production research for commercialization. Boronoi integrates artificial intelligence (AI) throughout the entire drug development process, from compound design and synthesis to deriving clinical candidates, significantly shortening development time.

PROTAC is a drug development platform based on small molecule compounds that induce protein degradation. It is expected to overcome the limitations of existing targeted anticancer drugs that cannot regulate specific proteins or develop resistance after long-term use, representing next-generation technology.

Lee Sung-yeol, CEO of JW Pharmaceutical, said, “Recently, fierce competition has emerged among many global pharmaceutical companies to secure targets and candidate compounds for PROTAC-based drug development. Through research cooperation with Boronoi, which possesses proprietary protein degradation technology and excellent research capabilities, we will expand our pipeline and continuously strengthen our research and development capabilities.”

This content was produced with the assistance of AI translation services.